Loading
PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.
The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.95, genetic association 0.00, clinical 0.99).
In plain words · PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.
PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.
The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH.
No product in this corpus aims at PSMB8 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMB8: RNA low tissue specificity; high antibody staining in 2 normal tissues; highest cancer staining renal cancer (11 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PSMB8 tissue; Open Targets ENSG00000204264 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Glynne et al, Nature, 1991, "A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC". Source.
Sources: HGNC HGNC:9545 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P28062 (protein name, function text, keywords and locations (REST API)); CIViC gene PSMB8 (1 evidence items, 0 assertions, 1 variants; diseases: Gastric Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000204264 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.62, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Involved in the generation of spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein. Acts as a major component of interferon gamma-induced sensitivity. Location: Cytoplasm; Nucleus (UniProt). Locus 6p21.32 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Cerebral cortex, Cervix, Colon.
Medium only: glioma, testis cancer, thyroid cancer.
HPA PSMB8 tissue · HPA PSMB8 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PSMB8" OR ABSTRACT:"PSMB8" OR TITLE:"proteasome 20S subunit beta 8" OR ABSTRACT:"proteasome 20S subunit beta 8" OR TITLE:"Proteasome subunit beta type-8" OR ABSTRACT:"Proteasome subunit beta type-8" OR TITLE:"RING10" OR ABSTRACT:"RING10" OR TITLE:"D6S216E" OR ABSTRACT:"D6S216E" OR TITLE:"PSMB5i" OR ABSTRACT:"PSMB5i") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMB8, not a curated reading list.